Key Quantitative Figures

  • Number of equity shares allotted: 38,442
  • Face value per share: ₹1
  • Exercise price per share: ₹860.00
  • Premium per share: ₹859.00
  • Pre-allotment paid-up share capital: 41,30,45,091 equity shares
  • Post-allotment paid-up share capital: 41,30,83,532 equity shares
  • Total issued share capital after allotment: ₹41,30,83,532
  • Distinctive number range: 41,30,45,091 to 41,30,83,532 (Both Inclusive)
  • ISIN Number: INE634S01028

Dates of Action

  • Date of circular resolution: November 19, 2026
  • Date of share issue: November 19, 2026
  • Previous filing date of statement under Regulation 10(b): September 27, 2023

Parties Involved

  • Approving authority: Nomination and Remuneration Committee of the Board of Directors
  • Stock exchanges: National Stock Exchange of India Limited (NSE) and BSE Limited (BSE)
  • Signing officer: Hitesh Kumar Jain, Company Secretary & Compliance Officer

Capital Structure Impact

The allotment has increased the company's paid-up share capital by 38,442 equity shares, resulting in a dilution of approximately 0.093% of the pre-allotment share capital. The new shares rank pari-passu with existing equity shares of the company.

Additional Details

  • Scheme title: Mankind Employee Stock Option Plan 2022
  • Company registered office: 208, Okhla Industrial Estate, Phase-III, New Delhi-110020
  • No lock-in restrictions apply to the allotted shares
  • No share certificate numbers applicable (demat form)
  • No listing fees payable for this issuance
  • The disclosure has been uploaded on the company website at www.mankindpharma.com